Nearly 4 years after the first chimeric antigen receptor (CAR) T-cell therapies got FDA approval, the transformative impact of the treatment on refractory hematologic malignancies…
The US Meals and Drug Administration (FDA) granted accelerated approval on July 24, 2020, for the chimeric antigen receptor (CAR) T-cell therapy brexucabtagene autoleucel (Tecartus)…
A CAR T-cell therapy identified as axicabtagene ciloleucel (axi-cel) drove cancer cells to undetectable ranges in nearly 80% of sufferers with improved non-Hodgkin lymphoma (NHL)…